For the quarter ending 2025-09-30, CRVO had $1,116,687 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -7,726,639 | -11,152,438 |
| Accretion of discount on marketable securities, net | 221,525 | 486,494 |
| Stock-based compensation expense | 291,717 | 858,182 |
| Prepaid expenses and other assets | -278,355 | 58,967 |
| Deferred grant revenue | - | 0 |
| Deferred offering costs | 105,977 | 163,354 |
| Accounts payable | -434,813 | 272,592 |
| Accrued expenses and other current liabilities | 454,084 | 428,169 |
| Grant receivable | -999,588 | 106,744 |
| Net cash used in operating activities | -6,465,210 | -10,409,054 |
| Purchase of marketable securities | 3,918,103 | 16,858,416 |
| Maturities of marketable securities | 11,500,000 | 22,000,000 |
| Net cash provided by (used in) investing activities | 7,581,897 | 5,141,584 |
| Proceeds from the sale of common stock, prefunded warrants and common stock warrants, net of offering costs | 0 | 0 |
| Sale of common stock under open market sales agreement, net of issuance costs-Open Market Sales Agreement | 0 | 4,588,687 |
| Net cash provided by financing activities | 0 | 4,588,687 |
| Net increase (decrease) in cash and cash equivalents | 1,116,687 | -678,783 |
| Cash and cash equivalents at beginning of period | 8,999,496 | - |
| Cash and cash equivalents at end of period | 9,437,400 | - |
CervoMed Inc. (CRVO)
CervoMed Inc. (CRVO)